|Bone morphogenetic protein receptor type II|
|Gene code:||HUGO code:BMPR2|
|Protein type:||Receptor serine/threonine kinase|
|Functions:||Receptor for TGF beta ligands - BMP's|
|Domains:||TM domain, S/T kinase|
|Taxa expressing:||Homo sapiens; homologs: many metazoan phyla|
|Cell types:||many; expressed highly in heart and liver|
|Subcellular localization:||Plasma membrane|
|Catalytic activity:||ATP + [receptor-protein] = ADP + [receptor-protein] phosphate|
|Cofactor(s):||Magnesium or manganese|
|Diseases:||Primary pulmonary hypertension (PPH1) Online 'Mendelian Inheritance in Man' (OMIM) 178600|
Bone morphogenetic protein receptor type II or BMPR2 is a serine/threonine receptor kinase. It binds Bone morphogenetic proteins, members of the TGF beta superfamily of ligands. BMPs are involved in host of cellular functions including osteogenesis, cell growth and cell differentiation. Signaling in the BMP pathway begins with the binding of a BMP to the the type II receptor. This causes the recruitment of a BMP type I receptor, which it phosphorylates. The Type I receptor phosphorylates an R-SMAD a transcriptional regulator.
|Locus||Chr. 2 q33|
Unlike the TGFβ type II receptor, which has a high affinity for TGF-β1, BMPR2 does not have a high affinity for BMP-2, BMP-7 and BMP-4, unless it is co-expressed with a type I BMP receptor. In TGF beta signaling all of the receptors exist in homodimers before ligand binding. In the case of BMP receptors only a small fraction of the receptors exist in homomeric forms before ligand binding. Once a ligand has bound to a receptor, the amount of homomeric receptor oligomers increase, suggesting that the equilibrium shifts towards the homodimeric form. The low affinity for ligands suggests that BMPR2 may differ in the from other type II TGF beta receptors in that the ligand may bind the type I receptor first.
- ↑ 1.0 1.1 Gilboa, L; Nohe A, Geissendorfer T, Sebald W, Henis YI, Knaus P. (Mar 2000). "Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors". Mol Biol Cell. 11 (3). Retrieved on 2006-07-03.
- ↑ Kirsch, T; Nickel J, Sebald W. (Jul 2000). "BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II". EMBO J. 19 (13). PubMed. Retrieved on 2006-07-03.
Cell signaling: TGF beta signaling pathway
|TGF beta superfamily of ligands||TGF beta family (TGF-β1, TGF-β2, TGF-β3)|
Bone morphogenetic proteins (BMP2, BMP3, BMP4, BMP5, BMP6, BMP7, BMP8a, BMP8b, BMP10 , BMP15)
Growth differentiation factors (GDF1, GDF2, GDF3, GDF5, GDF6, GDF7, Myostatin/GDF8, GDF9, GDF10, GDF11, GDF15)
Other (Activin A and B/Inhibin A and B, Anti-müllerian hormone, Nodal)
|TGF beta receptors||TGFBR1: Activin type 1 receptors (ACVR1, ACVR1B, ACVR1C) - ACVRL1 - BMPR1 (BMPR1A - BMPR1B) |
TGFBR2: Activin type 2 receptors (ACVR2A, ACVR2B) - AMHR2 - BMPR2
|Transducers/SMAD||R-SMAD (SMAD1, SMAD2, SMAD3, SMAD5, SMAD9) - I-SMAD (SMAD6, SMAD7) - SMAD4|
|Ligand Inhibitors||Cerberus - Chordin - DAN - Decorin - Follistatin - Gremlin - Lefty - LTBP1 - Noggin - THBS1|
|Coreceptors||BAMBI - Cripto|
Kinases: Serine/threonine-specific protein kinases (primarily EC 2.7.11)
|2.7.11||Pyruvate dehydrogenase kinase - Protein kinase A - Protein kinase G - Protein kinase C (Protein kinase Mζ) - Rhodopsin - Beta adrenergic receptor - G-protein coupled receptor kinases - Ca2+/calmodulin-dependent - Myosin light-chain) - Phosphorylase - Cyclin-dependent - Mitogen-activated (Extracellular signal-regulated, C-Jun N-terminal (MAPK8, MAPK9), P38 mitogen-activated protein) - MAP3K - GSK-3 - AMP-activated|
|2.7.12||MAP2K (1, 2, 3, 4, 5, 6, 7)|
|18.104.22.168, or unknown||Anti-Mullerian hormone receptor - Ataxia telangiectasia mutated - Aurora (A, B) - Mammalian target of rapamycin - Bone morphogenetic protein receptors (1, 2) - CDKL5 - c-Raf - EIF-2 - Ribosomal s6 - Protein kinase B - PDK1|
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies